Diagnostic Center | December 28, 2023
Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China
Innovent will supply sintilimab for the collaborated clinical trial
Innovent will supply sintilimab for the collaborated clinical trial
LG Chem will receive totaling up to $95.5 million for the China rights
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Approval to dramatically change CAR-T therapies landscape
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)